![]() |
市場調査レポート
商品コード
914940
医薬品・バイオ医薬品・機能性食品向け分析装置の世界市場:将来予測 (2025年まで)Global Analytical Instrumentation Market in Pharmaceuticals, Biopharmaceuticals, and Nutraceuticals, Forecast to 2025 |
医薬品・バイオ医薬品・機能性食品向け分析装置の世界市場:将来予測 (2025年まで) |
出版日: 2019年10月17日
発行: Frost & Sullivan
ページ情報: 英文 98 Pages
納期: 即日から翌営業日
|
世界の医薬品・バイオ医薬品・機能性食品向け分析装置の市場規模は、2018年の30億5670万米ドルから、2025年には49億1140万米ドルにまで拡大する見通しです。ただし、メーカー側には強い価格引き下げ圧力がかかるため、柔軟な価格戦略を構築して顧客に対応する必要があります。地域別ではアジア太平洋地域の成長が著しく、特に中国が研究開発 (R&D) の中核として台頭しつつあります。
当レポートでは、世界の医薬品・バイオ医薬品・機能性食品向け分析装置の市場について分析し、基本的な市場構造や主な促進・抑制要因、全体的な市場規模の動向見通し (今後8年間分)、分野別・地域別の詳細動向、業界関係者が今後取るべき戦略、といった情報を取りまとめてお届けいたします。
Global Analytical Instrumentation Market in Pharmaceuticals, Biopharmaceuticals, and Nutraceuticals, Forecast to 2025
The global pharmaceuticals, biopharmaceuticals, and neutraceuticals market includes market revenues of analytical instrumentation applied in the 3 segments. Analytical instruments are applied in research, development, manufacturing, quality control, and distribution of drugs. Some key applications include (and are not limited to) drug discovery and development testing, biopharmaceutical analytical testing, quality control testing, cancer research, and process technology analysis.
Neutraceutical includes analytical equipment used for functional food and beverages, dietary supplements, and herbals. Geographic scope is global. Different techniques, including chromatographs, mass spectrometers, infrared spectrometers, UV-Vis spectrometers, Raman spectrometers, thermal analyzers, and X-ray diffractometers are included under different applications. The total analytical instrumentation market in pharmaceuticals, biopharmaceuticals, and neutraceuticals was estimated at $3056.7 million in 2018, and is expected to reach $4911.4 million in 2025. There is a high pricing pressure on drug manufacturers to cut down costs. Hence, manufacturers would have to create a flexible pricing strategy to maximize their profits and negotiate with payers. Process analyzers that can be plugged in as part of the manufacturing process would reduce operating costs for manufacturers.
The pharmaceutical market in 2018 oversaw massive vertical integration of organizations. This would lead to cost efficiency and innovation in the industry.
Asia-Pacific is a large focus for pharmaceutical manufacturers, especially China. China has become a hub for innovation and R&D.
With the increasing approval for biosimilars in the United States, there would be significant cost cuts in the country, motivated by government institutions such as the National Health Service (NHS). The price differential between biosimilars and their branded counterparts is 30%. US political uncertainity and Brexit would negatively impact pharmaceutical market growth.
Manufacturers are offering exclusive biopharmaceutical solutions to resolve challenges associated with biological drugs. The intention of avoiding side effects-imposing small molecules and complex surgical procedures has led to targeted therapies of biologics. By 2020, analysts will expect biological drugs to capture about a quarter of the total small molecules market.
Growth of biological drugs is expected to continue, as biological blockbuster drugs keep entering the market. The penetration of biologic drugs will increase from 25% in 2016 to 30% in 2022.
Neutraceuticals are gaining importance and becoming a part of consumers' daily diet. Lifestyle, health disorders, and lack of exercise are leading to the segment's growth. Ingredients and raw material contamination, less awareness, and unclear regulations are challenging market growth.
Neutraceuticals are often dietary supplements or food additives. They offer benefits such as preventing and curing diseases. Functional beverages such as energy drinks that contain stimulants to make the brain active are also popular.